JUNSHI BIO (01877): Tropifor monoclonal antibody obtained approval for listing by the European Commission.

JUNSHI BIO (01877) announces that its product Toripalimab (European brand name: LOQTORZI) has recently been approved by the European Commission (EC) for two indications: Toripalimab in combination with cisplatin and gemcitabine for first-line treatment of recurrent, unresectable or refractory, or metastatic nasopharyngeal carcinoma in adults, and Toripalimab in combination with cisplatin and paclitaxel for first-line treatment of unresectable advanced/recurrent or metastatic esophageal squamous cell carcinoma in adults. This approval is applicable to all 27 EU member states as well as Iceland, Norway, and Liechtenstein. Toripalimab has become the first and only drug approved for the treatment of nasopharyngeal carcinoma in Europe, and the only drug approved in Europe for first-line treatment of advanced or metastatic esophageal squamous cell carcinoma regardless of PD-L1 expression. This approval is applicable to all 27 EU member states as well as Iceland, Norway, and Liechtenstein. Toripalimab has become the first and only drug approved for the treatment of nasopharyngeal carcinoma in Europe, and the only drug approved in Europe for first-line treatment of advanced or metastatic esophageal squamous cell carcinoma regardless of PD-L1 expression. The European market is an important component of the company's overseas commercialization strategy, and this approval is beneficial for further expanding the company's presence in overseas markets, enhancing the international influence of the company's products, and is expected to have a positive impact on the company's long-term business performance.